CC-115
- Generic Name
- CC-115
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N8O
- CAS Number
- 1228013-15-7
- Unique Ingredient Identifier
- FII75TFH5L
- Background
CC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT02833883
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 118
- Registration Number
- NCT01353625
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇩🇪Universitatsklinikum Wurzburg, Würzburg, Germany
🇺🇸UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath